News

This article compares sandwich vs competitive assays in ELISA and lateral flow, focusing on format selection, reagent strategy and assay development considerations.

Fleet Bioprocessing will be attending Sensors for Health 2026 at Swansea University on 29 April. The event brings together researchers and industry working in health related sensor development, diagnostics and translation.

Fleet Bioprocessing has been re-certified for Cyber Essentials, demonstrating effective controls against common cyber attacks under the UK government-backed scheme.

Performance verification is the stage at which a lateral flow assay moves from development understanding to formal analytical evidence. This article explains how intended use and design inputs shape verification strategy, how CLSI-guided studies are structured, and why robust documentation is critical for transfer, submission, and product readiness.

Preparing a lateral flow assay for transfer means moving from a feasible prototype to a process that can be controlled, reproduced, and sustained in manufacture. This article explores what transfer readiness really means, how robustness studies, pilot batches, documentation, training, and validation fit together, and how to establish a process that can support routine production.

This article explains how lateral flow assay scale-up and manufacture depend on robust design, material selection, process tolerances, reel-to-reel control, drying and assembly consistency.